A new Phase I clinical trial sponsored by the Vermont Cancer Center at the University of Vermont and Fletcher Allen Health Care has opened to test the investigational drug DFMO, or alpha-difluoromethy

Cardiovascular disease is the leading cause of death globally and a tremendous burden on the healthcare system.

An investigational intervention using naturally ocurring antibodies in human blood has preserved the thinking abilities of a group of mild- to moderate-stage Alzheimer's patients over 18 months and si

Bioheart, Inc.

An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer.

Stryker's Interventional Spine business unit today announced the release of its iVAS inflatable vertebral augmentation system, a minimally invasive device cleared for use in treating vertebral compres

Baxter International Inc.

biospace med announced today that it has raised $18 million to accelerate market expansion in North America and Europe of the company's FDA-cleared EOS ultra-low-dose 2D/3D imaging system.

It's illegal for health products with medical formulations to be accepted by the U.S.

ConforMIS, Inc. announced today that the iUni® G2 has received CE Mark certification, providing regulatory approval for ConforMIS to begin the sale of this products throughout the European Union.